Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amlodipine + valsartan + atorvastatin is a fixed-dose combination of three small molecule drugs used primarily for the management of cardiovascular risk factors. Amlodipine is a calcium channel blocker that relaxes blood vessels and reduces the workload on the heart by inhibiting calcium influx into vascular smooth muscle and cardiac muscle cells. Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to its receptor, leading to vasodilation and reduced blood pressure. Atorvastatin is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol levels by inhibiting the rate-limiting step in cholesterol biosynthesis in the liver. The combination targets hypertension, dyslipidemia, and overall cardiovascular risk reduction[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amlodipine + valsartan + atorvastatin.